RxDoctor Payments Data

Paul Sliskovich, MD

Family Medicine · Gardena, CANPI 1245892934

Payments from drug & device makers

$1,960in general payments, 2019–2025

Across 111 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$540
  • Amgen$211
  • AbbVie$203
  • Pfizer$175
  • Boehringer Ingelheim$91
  • Scilex Pharmaceuticals Inc.$81
  • plus $658 from 18 others

What the payments were for

  • Food & beverage$1,94099%
  • Education$211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,960 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$210,323
Medicare patients
240
Services billed
10,946

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol61$71,706
OzempicSemaglutide73$66,802
EliquisApixaban93$65,389
RybelsusSemaglutide33$61,053
MounjaroTirzepatide59$60,387
Repatha SureclickEvolocumab14$12,143
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$11,715
JanumetSitagliptin Phos/Metformin Hcl15$11,424
Xigduo XrDapaglifloz Propaned/Metformin13$9,518
Ondansetron Hcl36$3,762
TrintellixVortioxetine Hydrobromide13$3,192
Gabapentin143$2,418
Levothyroxine Sodium145$2,118
BreynaBudesonide/Formoterol Fumarate14$1,954
Atorvastatin Calcium184$1,853

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$540$127,855106 claims
AstraZenecaFarxiga$45$71,70661 claims
PfizerEliquis$175$65,38993 claims
Lilly USA, LLCMounjaro$74$60,38759 claims
GSKTrelegy Ellipta$63$11,71518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Gardena

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →